ZURA

Zura Bio Limited

Price Chart

Latest Quote

$5.45

+0.20 (+3.81%)

Current Price

Previous Close	$5.25
Open	$5.12
Day High	$5.59
Day Low	$5.06
Volume	739,318

Fetched: 2026-07-18T12:56:54

Stock Information

Shares Outstanding	94.88M
Cash Equivalents	$225.59M
Net Income	$-106.13M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$517.10M
EPS (TTM)	$-1.09
Exchange	NCM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$292.14M
Income	$-106.13M
Book/sh	$2.28
Cash/sh	$2.38
Employees	40

Financial Ratios

Quick Ratio	19.21
Current Ratio	19.33

Returns & Margins

ROA	-25.39%
ROE	-40.96%

Ownership

Insider Ownership	21.51%
Institutional Ownership	78.86%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-9.85
P/B	2.39

Analyst Data

Recommendation	strong_buy
Target Price	$15.67

Technical Indicators

SMA20	$5.05
SMA50	$4.50
SMA200	$4.92
RSI	51.35
ATR	0.4947

Shares Float	50.84M
Short Float	13.03%
Short Ratio	5.51
Volatility	-0.04
Rel Volume	0.45

Performance History

Week	+6.65%
Month	+55.05%
Quarter	-4.55%
6 Months	+1.49%
YTD	-1.80%
Year	+322.48%
3 Years	-14.17%
10 Years	-24.72%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-07-17	$5.45	758,400
2026-07-16	$5.25	789,500
2026-07-15	$5.39	689,900
2026-07-14	$5.06	791,300
2026-07-13	$5.15	1,181,300
2026-07-10	$5.11	1,254,600
2026-07-09	$5.51	1,103,500
2026-07-08	$5.49	1,188,100
2026-07-07	$5.08	1,261,300
2026-07-06	$5.36	926,100
2026-07-02	$5.17	906,400
2026-07-01	$5.01	1,683,900
2026-06-30	$5.90	2,763,100
2026-06-29	$5.63	2,454,700
2026-06-26	$5.35	9,625,500
2026-06-25	$4.54	1,289,000
2026-06-24	$4.26	863,600
2026-06-23	$4.30	1,247,500
2026-06-22	$4.23	1,376,900
2026-06-18	$3.75	1,765,900

About Zura Bio Limited

Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.

📰 Latest News

William Blair Starts Zura Bio (ZURA) at Outperform

Insider Monkey • 2026-07-14T18:09:12Z

Here's Why We're Not Too Worried About Zura Bio's (NASDAQ:ZURA) Cash Burn Situation

Simply Wall St. • 2026-06-03T10:09:26Z

One Zura Bio Insider Raised Their Stake In The Previous Year

Simply Wall St. • 2026-04-23T10:06:27Z

Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million

Motley Fool • 2026-02-25T20:26:18Z

This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges

Motley Fool • 2026-02-25T20:19:51Z

Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst

Motley Fool • 2026-02-25T20:11:16Z

Zura Bio Highlights Key Phase 2 Tibulizumab Readouts at Guggenheim Biotech Summit 2026

MarketBeat • 2026-02-16T11:03:10Z

December 2025's Top Penny Stocks With Promising Potential

Simply Wall St. • 2025-12-15T18:05:16Z

Bullish Outlook on Zura Bio Limited (ZURA) Amid Tibulizumab Phase 2 Clinical Trial Progress

Insider Monkey • 2025-11-29T06:26:01Z

Zura Bio And 2 Other Promising Penny Stocks For Your Watchlist

Simply Wall St. • 2025-10-28T12:05:05Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Total Expenses	$75,246,000	$55,189,000	$62,638,000	$27,162,000
Other Income Expense	$260,000	$-5,212,000	$-111,000	$-179,000
Other Non Operating Income Expenses	$260,000	$28,000	$-2,227,000	$-179,000
Net Non Operating Interest Income Expense	$6,336,000	$7,998,000	$2,186,000	$8,000
Operating Expense	$75,246,000	$55,189,000	$62,638,000	$27,162,000
General And Administrative Expense	$33,164,000	$30,788,000	$18,639,000	$3,473,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-68,650,000	$-52,403,000	$-60,360,000	$-25,738,000
Net Interest Income	$6,336,000	$7,998,000	$2,186,000	$8,000
Interest Income	$6,336,000	$7,998,000	$2,186,000	$8,000
Normalized Income	$-68,650,000	$-47,163,000	$-62,476,000	$-25,738,000
Net Income From Continuing And Discontinued Operation	$-68,650,000	$-52,403,000	$-60,360,000	$-25,738,000
Total Operating Income As Reported	$-75,246,000	$-55,189,000	$-62,638,000	$-27,162,000
Net Income Common Stockholders	$-99,353,000	$-45,386,000	$-69,243,000	$-32,390,000
Net Income	$-68,650,000	$-52,403,000	$-60,360,000	$-25,738,000
Net Income Including Noncontrolling Interests	$-68,650,000	$-52,403,000	$-60,563,000	$-27,333,000
Net Income Continuous Operations	$-68,650,000	$-52,403,000	$-60,563,000	$-27,333,000
Pretax Income	$-68,650,000	$-52,403,000	$-60,563,000	$-27,333,000
Interest Income Non Operating	$6,336,000	$7,998,000	$2,186,000	$8,000
Operating Income	$-75,246,000	$-55,189,000	$-62,638,000	$-27,162,000
Per Share
Diluted EPS	$-1.06	$-0.60	$-2.09	$-12.19
Basic EPS	$-1.06	$-0.60	$-2.09	$-12.19
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-75,197,000	$-49,940,000	$-64,754,000	$-27,162,000
Reconciled Depreciation	$49,000	$9,000	$0	-
EBITDA (Bullshit earnings)	$-75,197,000	$-55,180,000	$-62,638,000	$-27,162,000
EBIT	$-75,246,000	$-55,189,000	$-62,638,000	$-27,162,000
Diluted Average Shares	$94,160,138	$75,070,761	$33,064,036	$2,111,000
Basic Average Shares	$94,160,138	$75,070,761	$33,064,036	$2,111,000
Diluted NI Availto Com Stockholders	$-99,353,000	$-45,386,000	$-69,243,000	$-32,390,000
Otherunder Preferred Stock Dividend	$30,703,000	$-7,017,000	$8,883,000	$6,652,000
Tax Provision	$0	$0	$0	$0
Research And Development	$42,082,000	$24,401,000	$43,999,000	$23,689,000
Selling General And Administration	$33,164,000	$30,788,000	$18,639,000	$3,473,000
Other Gand A	$33,164,000	$30,788,000	$18,639,000	$3,473,000
Total Unusual Items	-	$-5,240,000	$2,116,000	$6,223,698
Total Unusual Items Excluding Goodwill	-	$-5,240,000	$2,116,000	$6,223,698
Minority Interests	-	$0	$203,000	$1,595,000
Gain On Sale Of Security	-	$-5,240,000	$2,116,000	$6,223,698

Fetched: 2026-07-13

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$101,538,000	$146,815,000	$59,330,000	$-32,056,000
Total Assets	$113,948,000	$179,533,000	$100,843,000	$5,262,000
Total Non Current Assets	$1,638,000	$789,000	$0	$3,486,000
Other Non Current Assets	$1,512,000	$698,000	-	$141,474,352
Current Assets	$112,310,000	$178,744,000	$100,843,000	$1,776,000
Other Current Assets	$2,903,000	$2,246,000	$1,037,000	$209,000
Cash Cash Equivalents And Short Term Investments	$109,407,000	$176,498,000	$99,806,000	$1,567,000
Cash And Cash Equivalents	$109,407,000	$176,498,000	$99,806,000	$1,567,000
Non Current Deferred Assets	-	-	$0	$3,486,000
Cash Equivalents	-	-	$97,913,000	-
Cash Financial	-	-	$1,893,000	$13,785
Prepaid Assets	-	-	-	$19,702
Debt
Net Debt	-	-	-	$6,189,000
Total Debt	-	-	-	$7,756,000
Current Debt And Capital Lease Obligation	-	-	-	$7,756,000
Current Debt	-	-	-	$7,756,000
Liabilities
Total Liabilities Net Minority Interest	$12,410,000	$19,514,000	$21,292,000	$27,318,000
Total Non Current Liabilities Net Minority Interest	$0	$0	$990,000	$12,500,000
Current Liabilities	$12,410,000	$19,514,000	$20,302,000	$14,818,000
Payables And Accrued Expenses	$9,091,000	$17,801,000	$19,101,000	$4,287,000
Payables	$1,279,000	$733,000	$2,749,000	$2,010,000
Accounts Payable	$1,279,000	$733,000	$2,749,000	$2,010,000
Derivative Product Liabilities	-	$0	$990,000	$0
Current Notes Payable	-	-	$0	$7,756,000
Non Current Deferred Liabilities	-	-	-	$4,010,000
Other Current Liabilities	-	-	-	$2,634,000
Equity
Common Stock Equity	$101,538,000	$146,815,000	$59,330,000	$-32,056,000
Total Equity Gross Minority Interest	$101,538,000	$160,019,000	$79,551,000	$-22,056,000
Stockholders Equity	$101,538,000	$146,815,000	$59,330,000	$-32,056,000
Retained Earnings	$-224,547,000	$-155,897,000	$-103,494,000	$-32,056,000
Preferred Securities Outside Stock Equity	-	-	$0	$12,500,000
Preferred Stock Equity	-	-	-	-
Other
Ordinary Shares Number	$73,680,710	$65,297,530	$43,593,678	$27,052,155
Share Issued	$73,680,710	$65,297,530	$43,593,678	$27,052,155
Tangible Book Value	$101,538,000	$146,815,000	$59,330,000	$-32,056,000
Invested Capital	$101,538,000	$146,815,000	$59,330,000	$-24,300,000
Working Capital	$99,900,000	$159,230,000	$80,541,000	$-13,042,000
Total Capitalization	$101,538,000	$146,815,000	$59,330,000	$-32,056,000
Minority Interest	$0	$13,204,000	$20,221,000	$10,000,000
Additional Paid In Capital	$326,078,000	$302,705,000	$162,820,000	$0
Capital Stock	$7,000	$7,000	$4,000	$0
Common Stock	$7,000	$7,000	$4,000	$0
Pensionand Other Post Retirement Benefit Plans Current	$3,319,000	$1,713,000	$1,201,000	$141,000
Current Accrued Expenses	$7,812,000	$17,068,000	$16,352,000	$2,277,000
Net PPE	$126,000	$91,000	$0	-
Preferred Stock	-	$0	$0	$0
Dueto Related Parties Current	-	-	-	$78,893

Fetched: 2026-07-13

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-64,928,000	$-33,151,000	$-23,054,000	$-13,202,000
Operating Activities
Operating Cash Flow	$-64,815,000	$-28,076,000	$-15,054,000	$-1,202,000
Cash Flow From Continuing Operating Activities	$-64,815,000	$-28,076,000	$-15,054,000	$-1,202,000
Operating Gains Losses	$-4,916,000	$5,213,000	$-741,000	$23,000
Investing Activities
Capital Expenditure	$-113,000	$-5,075,000	$-8,000,000	$-12,000,000
Investing Cash Flow	$-113,000	$-5,075,000	$-8,000,000	$-12,000,000
Cash Flow From Continuing Investing Activities	$-113,000	$-5,075,000	$-8,000,000	$-12,000,000
Financing Activities
Issuance Of Capital Stock	$5,096,000	$60,757,000	$116,407,000	$10,000,000
Financing Cash Flow	$-2,163,000	$109,843,000	$121,293,000	$14,769,000
Cash Flow From Continuing Financing Activities	$-2,163,000	$109,843,000	$121,293,000	$14,769,000
Net Other Financing Charges	$-7,366,000	$-944,000	$-1,184,000	$-2,831,000
Net Common Stock Issuance	$5,096,000	$60,757,000	$116,407,000	$0
Common Stock Issuance	$5,096,000	$60,757,000	$116,407,000	$0
Net Preferred Stock Issuance	-	-	$0	$10,000,000
Preferred Stock Issuance	-	-	$0	$10,000,000
Other
Interest Paid Supplemental Data	$0	$0	$0	$0
Income Tax Paid Supplemental Data	$0	$0	$0	$0
End Cash Position	$109,407,000	$176,498,000	$99,806,000	$1,567,000
Beginning Cash Position	$176,498,000	$99,806,000	$1,567,000	$0
Changes In Cash	$-67,091,000	$76,692,000	$98,239,000	$1,567,000
Proceeds From Stock Option Exercised	$107,000	$50,030,000	$16,070,000	$0
Net Intangibles Purchase And Sale	$0	$-5,000,000	$-8,000,000	$-12,000,000
Purchase Of Intangibles	$0	$-5,000,000	$-8,000,000	$-12,000,000
Net PPE Purchase And Sale	$-113,000	$-75,000	$0	-
Purchase Of PPE	$-113,000	$-75,000	$0	-
Change In Working Capital	$-3,634,000	$2,307,000	$5,116,000	$3,541,000
Change In Other Current Assets	$-814,000	$-698,000	$0	-
Change In Payables And Accrued Expense	$-2,163,000	$4,214,000	$5,944,000	$3,750,000
Change In Prepaid Assets	$-657,000	$-1,209,000	$-828,000	$-209,000
Other Non Cash Items	$4,000	-	$29,235,000	$22,077,000
Stock Based Compensation	$12,332,000	$16,798,000	$9,655,000	$334,000
Depreciation Amortization Depletion	$49,000	$9,000	$0	-
Depreciation And Amortization	$49,000	$9,000	$0	-
Net Foreign Currency Exchange Gain Loss	$84,000	$-27,000	$-17,000	$23,000
Net Income From Continuing Operations	$-68,650,000	$-52,403,000	$-60,563,000	$-27,333,000
Repayment Of Debt	-	$0	$-10,000,000	$0
Net Issuance Payments Of Debt	-	$0	$-10,000,000	$7,600,000
Net Short Term Debt Issuance	-	$0	$-10,000,000	$7,600,000
Short Term Debt Payments	-	$0	$-10,000,000	$0
Unrealized Gain Loss On Investment Securities	-	$0	$2,244,000	$156,000
Gain Loss On Investment Securities	-	$5,240,000	$-724,000	$-6,223,698
Issuance Of Debt	-	-	$0	$7,600,000
Short Term Debt Issuance	-	-	$0	$7,600,000
Net Long Term Debt Issuance	-	-	$-10,000,000	$0
Long Term Debt Payments	-	-	$-10,000,000	$0
Change In Accrued Expense	-	-	-	$912,053
Change In Payable	-	-	-	$288,293
Change In Account Payable	-	-	-	$288,293
Change In Receivables	-	-	-	$0

Fetched: 2026-07-13